MICHAEL J. KATIN, MD

Plain English
This study looked at how neoadjuvant hormone therapy (NHT) affects the risk of death in men with prostate cancer who are treated with a specific type of radiation therapy (brachytherapy) and have low or some risk factors for heart disease. It found that men with low-risk prostate cancer who used NHT had a 27% higher risk of dying from any cause compared to those who didn't use it, especially if they had at least one risk factor for heart disease. This is important because it shows that NHT may not be safe for all prostate cancer patients, especially those with low-risk cancer and heart disease risk factors. Who this helps: This helps patients with prostate cancer and their doctors by informing treatment decisions.

Plain English
This study compared two treatment options for men with high-risk prostate cancer: radical prostatectomy (RP), which is surgery to remove the prostate, and combined-modality therapy (CMT), which includes radiation and hormone therapy. Over an average follow-up of about 4.6 years, 21 men died from prostate cancer, but the study found that the risk of death from cancer was similar for both treatments, with no significant difference. Specifically, factors like a low PSA level (less than 4 ng/mL) were linked to a much higher risk of death, highlighting the importance of these indicators in assessing patient risk. Who this helps: This information benefits patients with high-risk prostate cancer and their doctors in making treatment decisions.

Plain English
This study looked at how a man's race affects the risk of dying after receiving brachytherapy, a treatment for localized prostate cancer. Among 5,360 men studied, African-American and Hispanic men had a significantly higher risk of death compared to Caucasian men, with risk levels of 1.77 and 1.79 times higher, respectively. Understanding these disparities is important for improving treatment approaches and outcomes for different racial groups in prostate cancer care. Who this helps: This research benefits patients and healthcare providers by highlighting the need for tailored treatment strategies based on race.

Plain English
This study looked at the relationship between heart procedures (coronary artery revascularization) and the risk of dying from prostate cancer in men who also have heart disease. Researchers found that men who had these heart procedures had a significantly lower risk of death (about 37% less) compared to those who did not have the procedures, despite having other serious health issues. Understanding this relationship is important because it suggests that treating heart disease can improve outcomes for men with prostate cancer. Who this helps: This helps men with prostate cancer and heart disease, as well as their doctors in making treatment decisions.

Plain English
This study looked at the use of an additional type of radiation treatment, called external beam radiotherapy (EBRT), in men with low-risk prostate cancer who were also receiving another treatment called brachytherapy from 1991 to 2007. Researchers found that the use of EBRT peaked at almost 25% in 2001 but dropped to just 3.3% by 2007, showing that fewer men opted for this combined treatment after updated guidelines were released. This matters because it reflects a shift in treatment practices that helps reduce potential side effects without compromising care for these patients. Who this helps: This benefits men with low-risk prostate cancer and their doctors.

Plain English
This study examined whether a combination treatment of total androgen blockade, which includes an LHRH agonist and an antiandrogen, is more effective than using an LHRH agonist alone in men with high-risk prostate cancer who received radiotherapy. Researchers followed 628 men for nearly 5 years and found that those on the combination therapy had an 82% lower risk of dying from prostate cancer compared to those on monotherapy. The results indicate that using both treatments together can significantly improve outcomes for these patients. Who this helps: This helps patients with high-risk prostate cancer.

Plain English
This study looked at elderly men with intermediate-risk prostate cancer to see what factors might predict death from the disease. Researchers found that men with heart disease had a significantly lower chance of dying from prostate cancer, with a risk reduction of 80% (meaning their chance of mortality was 0.20 times lower compared to those without heart disease). Additionally, higher prostate-specific antigen (PSA) levels were linked to an increased risk of death from prostate cancer. Who this helps: This information is useful for doctors treating elderly patients with prostate cancer, helping them assess risks based on heart health and PSA levels.

Plain English
The study looked at how different treatments influence the risk of dying from prostate cancer in men with a high risk of the disease. Researchers followed 1,342 men and found that those who received brachytherapy along with both androgen suppression therapy and external-beam radiation therapy had about a 68% lower risk of dying from prostate cancer compared to those who received no supplemental treatments. This matters because it provides important information on which treatment combinations are most effective for improving survival rates in high-risk prostate cancer patients. Who this helps: This helps men diagnosed with high-risk prostate cancer and their doctors in making informed treatment decisions.

Plain English
This study looked at a new treatment method for women with persistent or recurring pelvic cancers, using special catheters to deliver high doses of radiation directly to the tumors. Out of 14 women treated, 86% had excellent control of their cancer, with an average survival of about 21 months. This approach not only showed strong results but also had few complications, making it a promising option for many women facing this kind of cancer. Who this helps: Women with persistent or recurrent pelvic cancers.

Plain English
This study looks at how different factors, including genetics and environment, interact to influence health and disease, especially cancer. It finds that both genetic and environmental factors play significant roles in diseases, and the way we research cancer needs to be more integrated rather than overly specialized. This is important because it suggests a new approach to understanding and treating complex health issues, highlighting the need for a broader perspective in medical research. Who this helps: Patients and doctors involved in cancer treatment and research.